UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1360-4
Program Prior Authorization/Notification
Medication Lumakras™ (sotorasib)
P&T Approval Date 7/2021, 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Lumakras (sotorasib) is an inhibitor of the RAS GTPase family indicated for the treatment of
adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung
cancer (NSCLC) who have received at least one prior systemic therapy. The National
Comprehensive Cancer Network (NCCN) recommends the use of Lumakras as subsequent
therapy for the treatment of KRAS G12C-mutated recurrent, advanced, or metastatic NSCLC.
NCCN also recommends the use of Lumakras as subsequent therapy for the treatment of KRAS
G12C-mutated pancreatic adenocarcinoma, ampullary adenocarcinoma, colon cancer, and rectal
cancer.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Lumakras will be approved based on the following criterion:
a. Member is less than 19 years of age
Authorization will be issued for 12 months.
B. Non-Small Cell Lung Cancer (NSCLC)
1. Initial Authorization
a. Lumakras will be approved based on all of the following criteria:
(1) Diagnosis of non-small cell lung cancer (NSCLC)
-AND-
© 2024 UnitedHealthcare Services Inc.
1
(2) Disease is one of the following:
(a) Recurrent
(b) Advanced
(c) Metastatic
-AND-
(3) Tumor is KRAS G12C-mutated
-AND-
(4) Patient has received at least one prior systemic therapy (e.g., immune
checkpoint inhibitor, platinum-based chemotherapy)
Authorization will be issued for 12 months.
2. Reauthorization
a. Lumakras will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Lumakras
therapy
Authorization will be issued for 12 months.
C. Pancreatic Adenocarcinoma
1. Initial Authorization
a. Lumakras will be approved based on all of the following criteria:
(1) Diagnosis of pancreatic adenocarcinoma
-AND-
(2) Disease is one of the following:
(a) Recurrent
(b) Advanced
(c) Metastatic
-AND-
(3) Tumor is KRAS G12C-mutated
-AND-
(4) Patient has received at least one prior systemic therapy (e.g., immune
checkpoint inhibitor, platinum-based chemotherapy)
© 2024 UnitedHealthcare Services Inc.
2
Authorization will be issued for 12 months.
2. Reauthorization
a. Lumakras will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Lumakras
therapy
Authorization will be issued for 12 months.
D. Ampullary Adenocarcinoma
1. Initial Authorization
a. Lumakras will be approved based on all of the following criteria:
(1) Diagnosis of ampullary adenocarcinoma
-AND-
(2) Disease is one of the following:
(a) Recurrent
(b) Advanced
(c) Metastatic
-AND-
(3) Tumor is KRAS G12C-mutation positive
-AND-
(4) Patient has received at least one prior systemic therapy (e.g., immune
checkpoint inhibitor, platinum-based chemotherapy)
Authorization will be issued for 12 months.
2. Reauthorization
a. Lumakras will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Lumakras
therapy
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services Inc.
3
E. Colorectal Cancer
1. Initial Authorization
a. Lumakras will be approved based on all of the following criteria:
(1) Diagnosis of one of the following:
(a) Colon Cancer
(b) Rectal Cancer
-AND-
(2) Disease is one of the following:
(a) Recurrent
(b) Advanced
(c) Metastatic
-AND-
(3) Tumor is KRAS G12C-mutation positive
-AND-
(4) Patient has received at least one prior systemic therapy (e.g., immune
checkpoint inhibitor, platinum-based chemotherapy)
Authorization will be issued for 12 months.
2. Reauthorization
a. Lumakras will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Lumakras
therapy
Authorization will be issued for 12 months.
F. NCCN Recommended Regimens
a. The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services Inc.
4
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Lumakras [package insert]. Thousand Oaks, CA: Amgen, Inc; April 2023.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
www.nccn.org. May 16, 2024.
Program Prior Authorization/Notification – Lumakras (sotorasib)
Change Control
7/2021 New program.
7/2022 Annual review. Expanded coverage criteria to include “recurrent”
disease per current NCCN guidelines. Added state mandate disclaimer
and updated references.
7/2023 Annual review. Updated background and criteria to include coverage of
pancreatic adenocarcinoma per NCCN guidelines. Updated references.
7/2024 Annual review. Added criteria for ampullary adenocarcinoma, colon
cancer, and rectal cancer per NCCN guidelines. Updated background
and references.
© 2024 UnitedHealthcare Services Inc.
5